3475-21-6Relevant articles and documents
Pentacyclic Cage Formation in the Intramolecular Addition of Tricyclic Nitrones
Mackay, Donald,Watson, Kenneth N.
, p. 777 (1982)
Despite their anti-configurations three tricyclic nitrones, on heating in toluene, undergo high-yield intramolecular addition to give the corresponding pentacyclic cages; a co-product from heating two of the nitrones in tetrachloroethylene is the pyridyl ketone.
Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19
Zhang, Jian-Wei,Xiong, Yuan,Wang, Feng,Zhang, Fu-Mao,Yang, Xiaodi,Lin, Guo-Qiang,Tian, Ping,Ge, Guangbo,Gao, Dingding
, (2021/12/09)
The epidemic coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread worldwide and efficacious therapeutics are urgently needed. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive drug target for fighting COVID-19. Herein, we report the discovery of 9,10-dihydrophenanthrene derivatives as non-peptidomimetic and non-covalent inhibitors of the SARS-CoV-2 3CLpro. The structure-activity relationships of 9,10-dihydrophenanthrenes as SARS-CoV-2 3CLpro inhibitors have carefully been investigated and discussed in this study. Among all tested 9,10-dihydrophenanthrene derivatives, C1 and C2 display the most potent SARS-CoV-2 3CLpro inhibition activity, with IC50 values of 1.55 ± 0.21 μM and 1.81 ± 0.17 μM, respectively. Further enzyme kinetics assays show that these two compounds dose-dependently inhibit SARS-CoV-2 3CLpro via a mixed-inhibition manner. Molecular docking simulations reveal the binding modes of C1 in the dimer interface and substrate-binding pocket of the target. In addition, C1 shows outstanding metabolic stability in the gastrointestinal tract, human plasma, and human liver microsome, suggesting that this agent has the potential to be developed as an orally administrated SARS-CoV-2 3CLpro inhibitor.
gamma-alkenyl ketone and preparation method thereof
-
Paragraph 0232-0236, (2020/02/29)
The invention discloses a gamma-alkenyl ketone preparation method, wherein the target product can be obtained at high yield and high regioselectivity by using acetophenone and 1,3-butadiene as raw materials in the presence of an organic solvent, a catalyst, an additive and a ligand. According to the invention, the method has advantages of high atom economy, high regioselectivity, high yield and the like, can achieve the efficient conversion from a cheap basic organic chemical product 1,3-butadiene to high-added-value gamma-alkenyl ketone, and uses the cheap catalyst, so that the reaction conditions are neutral and mild, and the experimental operation is safe and simple; and the synthesized gamma-alkenyl ketone is a useful synthetic intermediate, can be subjected to a series of conversionsto obtain a series of drug molecule precursors or key intermediates, and has wide application prospect.